Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 5
2019 2
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S. Graham MJ, et al. N Engl J Med. 2017 Jul 20;377(3):222-232. doi: 10.1056/NEJMoa1701329. Epub 2017 May 24. N Engl J Med. 2017. PMID: 28538111 Free article. Clinical Trial.
METHODS: We evaluated antisense oligonucleotides (ASOs) targeting Angptl3 messenger RNA (mRNA) for effects on plasma lipid levels, triglyceride clearance, liver triglyceride content, insulin sensitivity, and atherosclerosis in mice. ...CONCLUSIONS: …
METHODS: We evaluated antisense oligonucleotides (ASOs) targeting Angptl3 messenger RNA (mRNA) for effects on pl …
Advances in lipid-lowering therapy through gene-silencing technologies.
Nordestgaard BG, Nicholls SJ, Langsted A, Ray KK, Tybjærg-Hansen A. Nordestgaard BG, et al. Nat Rev Cardiol. 2018 May;15(5):261-272. doi: 10.1038/nrcardio.2018.3. Epub 2018 Feb 8. Nat Rev Cardiol. 2018. PMID: 29417937 Review.
Both antisense oligonucleotide inhibition and small interfering RNA technology aim to degrade gene mRNA transcripts to reduce protein production and plasma lipoprotein levels. ...The reported adverse effects of these new therapies include injection-site reactions, f …
Both antisense oligonucleotide inhibition and small interfering RNA technology aim to degrade gene mRNA transcripts to reduce protein …
Therapeutic oligonucleotides in cardiovascular and metabolic diseases: insights for the internist.
Girelli D, Busti F, Marchi G, Martinelli N, Olivieri O. Girelli D, et al. Intern Emerg Med. 2018 Apr;13(3):313-318. doi: 10.1007/s11739-018-1810-5. Epub 2018 Mar 1. Intern Emerg Med. 2018. PMID: 29498010
Indeed, subjects with null mutations in certain genes controlling lipoprotein metabolism like PCSK9 or ANGPTL-3 have a lower risk of cardiovascular disease. Since the complete absence of such proteins does not appear to carry any negative health effect, the c …
Indeed, subjects with null mutations in certain genes controlling lipoprotein metabolism like PCSK9 or ANGPTL-3 have a lower risk of …
Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data.
Strilchuk L, Fogacci F, Cicero AF. Strilchuk L, et al. Expert Opin Drug Saf. 2019 Jul;18(7):611-621. doi: 10.1080/14740338.2019.1620730. Epub 2019 May 29. Expert Opin Drug Saf. 2019. PMID: 31100030 Review.
INTRODUCTION: Cardiovascular (CV) diseases are the leading cause of death and disability in the developed countries. Lipid-lowering therapy is a cornerstone of the CV risk modification strategy. ...After an attentive literature search, the authors resumed here information …
INTRODUCTION: Cardiovascular (CV) diseases are the leading cause of death and disability in the developed countries. Lipid-lowering t …
ANGPTL3 Inhibitors - Their Role in Cardiovascular Disease Through Regulation of Lipid Metabolism.
Geladari E, Tsamadia P, Vallianou NG. Geladari E, et al. Circ J. 2019 Jan 25;83(2):267-273. doi: 10.1253/circj.CJ-18-0442. Epub 2018 Nov 30. Circ J. 2019. PMID: 30504621 Free article. Review.
Although ANGPTLs cannot bind the angiopoietin receptors expressed on endothelial cells, 2 ANGPTL family members (ANGPTL3 and ANGPTL4) have clinical importance because of their unambiguous effects on lipoprotein metabolism in mice and humans. ...Thus, ongoing …
Although ANGPTLs cannot bind the angiopoietin receptors expressed on endothelial cells, 2 ANGPTL family members (ANGPTL3 and ANGPTL4) …
RNA-targeted therapeutics for lipid disorders.
Tsimikas S. Tsimikas S. Curr Opin Lipidol. 2018 Dec;29(6):459-466. doi: 10.1097/MOL.0000000000000549. Curr Opin Lipidol. 2018. PMID: 30234555 Review.
PURPOSE OF REVIEW: To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed. ...Small inhibiting RNA (siRNA) molecules targeting proprotein convertase subtilisin kexin type 9 to reduce LDL-C, and …
PURPOSE OF REVIEW: To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effe
Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M, Zimetti F, Adorni MP, Sirtori CR, Lupo MG, Ferri N. Ruscica M, et al. Pharmacol Res. 2020 Mar;153:104653. doi: 10.1016/j.phrs.2020.104653. Epub 2020 Jan 10. Pharmacol Res. 2020. PMID: 31931117 Review.
The relevance of ANGPTL3 and ANGPTL4 as new therapeutic targets is proven by the development of monoclonal antibodies or antisense oligonucleotides. ...Similar evidence has been observed with the antisense oligonucleotide ANGPTL3-L(RX). The gene …
The relevance of ANGPTL3 and ANGPTL4 as new therapeutic targets is proven by the development of monoclonal antibodies or antisense
Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits.
Cho KI, Sakuma I, Sohn IS, Hayashi T, Shimada K, Koh KK. Cho KI, et al. Circ J. 2018 Mar 23;82(4):937-943. doi: 10.1253/circj.CJ-17-1445. Epub 2018 Mar 2. Circ J. 2018. PMID: 29503409 Free article. Review.
However, statins dose-dependently increase adverse effects and increase the risk of type 2 diabetes. Previously, it was hypothesized this was caused by to off-target effects, but recent studies demonstrate it is caused by on-target effects. ...Ezetimibe, PCSK …
However, statins dose-dependently increase adverse effects and increase the risk of type 2 diabetes. Previously, it was hypothesized …
Feedback